CTAD | Beckman Coulter
2026_CTAD_Boston

Clinical Trials in Alzheimer’s Disease

November 16 – 19, 2026

Developing assays to deepen the understanding of neurodegenerative conditions such as Alzheimer’s disease—From Discovery to Diagnosis

Meet us

 

Reimagining Neurodegenerative Disease Diagnostics

Through R&D innovations and collaborative partnerships, we're investing in cutting-edge research to open the door for new assay development.
Join us at CTAD2026 and speak to our experts about blood-based biomarkers for neurodegenerative diseases.

MAPSS-3402-GBL-EN-v1